Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00581425 · ClinicalTrials.gov registry record · Phase 4
Intron-A/Aldara Combination Therapy for Basal Cell Carcinoma (BCC)
A Phase 4 study of Basal Cell Carcinoma, sponsored by The University of Texas Health Science Center, Houston.
- Completed
- Registry status
- Phase 4
- Development phase
- 49
- Enrollment target
- 1
- Study location
NCT00581425 is a Phase 4 study of Basal Cell Carcinoma that has completed, run by The University of Texas Health Science Center, Houston. The registered enrollment target is 49 participants, below the 102-participant average among 24 other Basal Cell Carcinoma trials with a reported enrollment target (52% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00581425, a Phase 4 study of Basal Cell Carcinoma, has completed, sponsored by The University of Texas Health Science Center, Houston.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 49 participants
- Enrollment target
- 1
- Study location
Study Summary
A trial to see if BCC excluding the scalp and face can be treated successfully with a combination therapy of Intron-A and Aldara.
Conditions Studied
Interventions
- BIOLOGICAL Imiquimod and Interferon alpha
Study Locations (1)
Texas
- University of Texas Health Science Center of Houston Dermatology Clinic - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2007-12 |
| Est. Completion | 2011-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00581425
The ClinicalTrials.gov registry entry for NCT00581425 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 102-participant average among 24 other Basal Cell Carcinoma trials with a reported enrollment target (52% lower). The listed sponsor is The University of Texas Health Science Center, Houston, which has 732 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Basal Cell Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which Imiquimod and Interferon alpha is the first listed.
NCT00581425 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT00581425 about?
NCT00581425 is a clinical study titled "Intron-A/Aldara Combination Therapy for Basal Cell Carcinoma (BCC)". A trial to see if BCC excluding the scalp and face can be treated successfully with a combination therapy of Intron-A and Aldara.
What is the current status of trial NCT00581425?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 49 participants. The study started on 2007-12. Estimated completion is 2011-09.
What conditions does trial NCT00581425 study?
This clinical trial studies the following conditions: Basal Cell Carcinoma.
What interventions are being tested in trial NCT00581425?
The interventions under investigation include: Imiquimod and Interferon alpha (BIOLOGICAL).
Who is sponsoring clinical trial NCT00581425?
This trial is sponsored by The University of Texas Health Science Center, Houston, which has 732 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00581425 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Basal Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma
RECRUITING · Phase 2
-
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
RECRUITING · Phase 1
-
A Beta-only IL-2 ImmunoTherapY Study
RECRUITING · Phase 1
-
Neoadjuvant Nivolumab + Relatlimab (Opdualag) Versus Nivolumab for Resectable High-Risk Basal Cell Carcinoma
RECRUITING · Phase 2
-
Study to Investigate the Efficacy and Safety of RP1 in Adult Patients With Organ Transplants and Advanced Skin Malignancies
RECRUITING · Phase 1
-
Investigation of Standard Excision Surgical Margins Using Two Photon Fluorescence Microscopy
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.